Background The current study is aimed to examine the impact of pharmacokinetics and
gene polymorphisms of enzymes involving in absorption, distribution, metabolism and …

Skin rash, diarrhea and hepatotoxicity are the most common toxicities of Gefitinib, an
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. The present study …

Objectives Gefitinib is a potent epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor and is a key drug for patients with EGFR mutation-positive advanced non-small cell …

Aims: The current study investigates whether or not functional polymorphisms in the ATP-
binding cassette transporter gene ABCG2 might affect gefitinib activity and/or toxicity in non …

Conventional chemotherapeutic regimens have limited impact against most solid tumors
and deal with significant toxicity. Over the last 10 years, novel anticancer treatments …

Gefitinib has been available in the market for 20 years, but its pharmacokinetic mechanism
of response is little known. In this study, we examined the pharmacokinetic and metabolomic …

Introduction The present study investigated the effects of patients' genetic variations in the
pharmacokinetics of gefitinib at steady-state. We analyzed 31 Japanese patients with non …

Conventional chemotherapeutic regimens have limited impact against most solid tumors
and deal with significant toxicity. During the last years novel anticancer treatments targeting …

Gefitinib (Iressa, AstraZeneca) has been widely used for the treatment of locally advanced or
metastatic non-small cell lung cancer. A number of studies have been reported on its …

Background Gefitinib is frequently used to treat patients with non-small cell lung cancer
(NSCLC) and is excreted out from cells via the ATP-binding cassette transporter ABCG2 …